{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:09:33Z","timestamp":1778602173734,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"unspecified","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002108","name":"FARA","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017032","name":"Larimar Therapeutics","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100017032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002108","name":"Friedreich\u2019s Ataxia Research Alliance","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FDA","award":["R01FD006029-01"],"award-info":[{"award-number":["R01FD006029-01"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,3,4]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Novel therapeutics for Friedreich ataxia employ diverse strategies to increase frataxin protein levels, and a better understanding of the relation to clinical outcomes could strengthen their use as pharmacodynamic markers, and potentially as surrogate endpoint in therapeutic development. An elaborate modelling framework was developed to evaluate the suitability of frataxin as a biomarker across assays, tissues and disease stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Frataxin levels generated previously through two distinct assay platforms and from two separate clinical cohorts: whole blood frataxin was measured by a lateral-flow immunoassay (LF cohort), and a triple-quadrupole LC-MS\/MS method (TQ cohort), which enables separate quantification of mature frataxin (FXN-M) and erythrocyte-specific frataxin (FXN-E). Results were compared descriptively with control and heterozygous carriers, and several distinct modelling strategies were employed to correlate them with clinical function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both cohorts represented the relevant disease spectrum, with minor differences in both genetic and clinical severity, which correlated with frataxin levels. Heterozygous carriers showed intermediate levels. Modelling confirmed the predictive value of frataxin across multiple clinical assessments, such as age of symptom onset, age at loss of ambulation and long-term progression. GAA1, the shorter repeat expansion, was confirmed as the dominant predictor of frataxin itself, and, in most situations, clinical function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion<\/jats:title>\n                    <jats:p>Although isoform biology and tissue-specific expression remain important considerations, peripheral frataxin quantification provides biologically grounded measure of the pathophysiology and disease progression, with strong potential for application in therapeutic trials. Frataxin is a valid clinical biomarker, and our findings support advancing its candidacy as a surrogate endpoint in Friedreich ataxia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2026-001561","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:10:20Z","timestamp":1774282220000},"page":"e001561","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral frataxin levels govern long-term clinical progression in Friedreich ataxia"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-911X","authenticated-orcid":false,"given":"Christian","family":"Rummey","sequence":"first","affiliation":[{"name":"Clinical Data Science GmbH, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A","family":"Blair","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clementina","family":"Mesaros","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerapat","family":"Rojsajjakul","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yina","family":"Dong","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"},{"name":"The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Wilmot","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Zesiewicz","sequence":"additional","affiliation":[{"name":"Neurology, University of South Florida, Tampa, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Mathews","sequence":"additional","affiliation":[{"name":"The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C","family":"Hoyle","sequence":"additional","affiliation":[{"name":"Ohio State University, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Seeberger","sequence":"additional","affiliation":[{"name":"University of Colorado, Denver, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise A","family":"Corben","sequence":"additional","affiliation":[{"name":"Bruce Lefroy Centre for Genetic Health Research, Murdoch Children\u2019s Research Institute, Parkville, Victoria, Australia"},{"name":"Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin Bruce","family":"Delatycki","sequence":"additional","affiliation":[{"name":"Bruce Lefroy Centre for Genetic Health Research, Murdoch Children\u2019s Research Institute, Parkville, Victoria, Australia"},{"name":"Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S","family":"Finkel","sequence":"additional","affiliation":[{"name":"Pediatrics, St Jude Children\u2019s Research Hospital, Memphis, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H","family":"Roxburgh","sequence":"additional","affiliation":[{"name":"Neurology, Auckland City Hospital, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Duquette","sequence":"additional","affiliation":[{"name":"Service de Neurologie, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Yoon","sequence":"additional","affiliation":[{"name":"Divisions of Neurology and Clinical and Metabolic Genetics, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M","family":"Gomez","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-9240","authenticated-orcid":false,"given":"S H","family":"Subramony","sequence":"additional","affiliation":[{"name":"Department of Neurology and Fixel Institute for Neurological Disorders, University of Florida College of Medicine, Gainesville, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Perlman","sequence":"additional","affiliation":[{"name":"Neurology, UCLA, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shana","family":"Mccormack","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"},{"name":"The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Lynch","sequence":"additional","affiliation":[{"name":"Neurology, The Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026051208153117000_8.1.e001561.1","doi-asserted-by":"publisher","DOI":"10.2147\/jmdh.s292945"},{"key":"2026051208153117000_8.1.e001561.2","unstructured":"Bidichandani SI , Delatycki MB , Napierala M , et al . Friedreich ataxia. In: Adam MP , ed. GeneReviews. University of Washington, Seattle, Seattle (WA), 1993."},{"key":"2026051208153117000_8.1.e001561.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5254.1423"},{"key":"2026051208153117000_8.1.e001561.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.05.023"},{"key":"2026051208153117000_8.1.e001561.5","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29687"},{"key":"2026051208153117000_8.1.e001561.6","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/acn3.52027","article-title":"Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohort","volume":"11","author":"Shen","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208153117000_8.1.e001561.7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/acn3.225","article-title":"Frataxin levels in peripheral tissue in Friedreich ataxia","volume":"2","author":"Lazaropoulos","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208153117000_8.1.e001561.8","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1021\/acs.analchem.7b04590","article-title":"Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich\u2019s Ataxia","volume":"90","author":"Guo","year":"2018","journal-title":"Anal Chem"},{"key":"2026051208153117000_8.1.e001561.9","doi-asserted-by":"crossref","unstructured":"Wang Q , Laboureur L , Weng L , et al . Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich\u2019s Ataxia Blood. Front Neurosci 2022;16. doi:10.3389\/fnins.2022.874768","DOI":"10.3389\/fnins.2022.874768"},{"key":"2026051208153117000_8.1.e001561.10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s00415-023-12118-x","article-title":"Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohort","volume":"271","author":"Lynch","year":"2024","journal-title":"J Neurol"},{"key":"2026051208153117000_8.1.e001561.11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306788"},{"key":"2026051208153117000_8.1.e001561.12","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.207472"},{"key":"2026051208153117000_8.1.e001561.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2009.11.036"},{"key":"2026051208153117000_8.1.e001561.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.03.019"},{"key":"2026051208153117000_8.1.e001561.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2010.07.001"},{"key":"2026051208153117000_8.1.e001561.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2010.12.003"},{"key":"2026051208153117000_8.1.e001561.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063958","article-title":"Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich\u2019s ataxia","volume":"8","author":"Plasterer","year":"2013","journal-title":"PLoS One"},{"key":"2026051208153117000_8.1.e001561.18","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23789"},{"key":"2026051208153117000_8.1.e001561.19","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25934"},{"key":"2026051208153117000_8.1.e001561.20","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29286"},{"key":"2026051208153117000_8.1.e001561.21","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200034","article-title":"Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomised Controlled Trial (FRAMES)","volume":"8","author":"Pandolfo","year":"2022","journal-title":"Neurol Genet"},{"key":"2026051208153117000_8.1.e001561.22","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14737175.2017.1356721","article-title":"Pharmacological therapeutics in Friedreich ataxia: the present state","volume":"17","author":"Strawser","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"2026051208153117000_8.1.e001561.23","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-025-01054-5","article-title":"Nomlabofusp, a Fusion Protein of Human Frataxin and a Cell Penetrant Peptide, Delivers Mature and Functional Frataxin into Mitochondria","volume":"27","author":"Baile","year":"2025","journal-title":"AAPS J"},{"key":"2026051208153117000_8.1.e001561.24","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ymthe.2018.06.006","article-title":"Frataxin Restoration in the Nervous System: Possibilities for Gene Therapy","volume":"26","author":"Lynch","year":"2018","journal-title":"Mol Ther"},{"key":"2026051208153117000_8.1.e001561.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.006"},{"key":"2026051208153117000_8.1.e001561.26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3510"},{"key":"2026051208153117000_8.1.e001561.27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1323491","article-title":"Gene editing improves endoplasmic reticulum-mitochondrial contacts and unfolded protein response in Friedreich\u2019s ataxia iPSC-derived neurons","volume":"15","author":"Mishra","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026051208153117000_8.1.e001561.28","doi-asserted-by":"crossref","first-page":"101529","DOI":"10.1016\/j.scr.2019.101529","article-title":"Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich\u2019s ataxia cardiomyocytes","volume":"40","author":"Li","year":"2019","journal-title":"Stem Cell Res"},{"key":"2026051208153117000_8.1.e001561.29","doi-asserted-by":"crossref","unstructured":"Rummey C , et al . Test\u2013retest reliability of the Friedreich\u2019s ataxia rating scale. Ann Clin Transl Neurol 2020;5.","DOI":"10.1002\/acn3.51118"},{"key":"2026051208153117000_8.1.e001561.30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/acn3.332","article-title":"Progression of Friedreich ataxia: quantitative characterization over 5 years","volume":"3","author":"Patel","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208153117000_8.1.e001561.31","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22912"},{"key":"2026051208153117000_8.1.e001561.32","first-page":"e1499","article-title":"Natural History of Friedreich Ataxia: Heterogeneity of Neurologic Progression and Consequences for Clinical Trial Design","volume":"99","author":"Rummey","year":"2022","journal-title":"Neurology (ECronicon)"},{"key":"2026051208153117000_8.1.e001561.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.11.006","article-title":"Predictors of loss of ambulation in Friedreich\u2019s ataxia","volume":"18","author":"Rummey","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026051208153117000_8.1.e001561.34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/acn3.52057","article-title":"Evaluating mFARS in pediatric Friedreich\u2019s ataxia: Insights from the FACHILD study","volume":"11","author":"Rummey","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208153117000_8.1.e001561.35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41582-025-01065-y","article-title":"A global perspective on research advances and future challenges in Friedreich ataxia","volume":"21","author":"Indelicato","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"2026051208153117000_8.1.e001561.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.2041-210x.2012.00261.x"},{"key":"2026051208153117000_8.1.e001561.37","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.3390\/ijms26114969","article-title":"Long-Read Sequencing Identifies Mosaic Sequence Variations in Friedreich\u2019s Ataxia-GAA Repeats","volume":"26","author":"Park","year":"2025","journal-title":"IJMS"},{"key":"2026051208153117000_8.1.e001561.38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147507","article-title":"Interruptions of the FXN GAA Repeat Tract Delay the Age at Onset of Friedreich\u2019s Ataxia in a Location Dependent Manner","volume":"22","author":"Nethisinghe","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026051208153117000_8.1.e001561.39","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1021\/acs.analchem.3c00091","article-title":"Liquid Chromatography-Mass Spectrometry Analysis of Frataxin Proteoforms in Whole Blood as Biomarkers of the Genetic Disease Friedreich\u2019s Ataxia","volume":"95","author":"Rojsajjakul","year":"2023","journal-title":"Anal Chem"},{"key":"2026051208153117000_8.1.e001561.40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189990","article-title":"Somatic instability of the expanded GAA repeats in Friedreich\u2019s ataxia","volume":"12","author":"Long","year":"2017","journal-title":"PLoS One"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:16:22Z","timestamp":1778598982000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2026-001561"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001561","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}